Theta burst Transcranial Magnetic Stimulation (TMS) for Methamphetamine use disorder– A feasibility study to inform a multi-site Randomised Control Trial

Hunter New England Local Health District Drug and Alcohol Clinical Services0 个研究点目标入组 30 人开始时间: 2022年5月27日最近更新: 2023年3月13日

试验速览

暂无简介。

•Other psychoactive substance use requiring withdrawal management pharmacotherapy in the 28 days preceding eligibility screening (e.g. alcohol withdrawal requiring diazepam)
•Current pharmacotherapy for amphetamine use disorder (e.g. dexamphetamine) in the 28 days preceding eligibility screening.
•Current diagnosis of bipolar disorder, schizoaffective disorder, schizophrenia, that is deemed by research team psychiatrists not to have been drug-induced. Psychotic disorder not associated with drug use per DSM 5 criteria. Psychosis not otherwise specified (NOS), in remission, or drug-induced psychotic episodes are not exclusion criteria since these may be related to methamphetamine misuse.
•Severe uncontrolled medical condition, diagnosis of neurological disorder or neurocognitive disorder. Prior neurosurgical procedure.
•Contraindications to TMS (e.g. patients with epilepsy or seizure disorder, patients with implanted ferromagnetic equipment in their face or skull near the stimulation target, Cochlear implants, metal implant or electronic devices in the head, brain aneurysm clips/coils, VNS, pacemakers, deep brain stimulation, VP shunts, brain or neck stents, epilepsy, medical pump, hearing disorder, recent head injury).
•Current or planned pregnancy
•History of ECT treatment within the past three months.
•History of any previous TMS treatment.

发起方

Hunter New England Local Health District Drug and Alcohol Clinical Services